Antiepileptic effects of exogenous &beta;‑hydroxybutyrate on kainic acid‑induced epilepsy

Si,Jianping; Wang,Yingyan; Xu,Jing; Wang,Jiwen

doi:10.3892/etm.2020.9307

Antiepileptic effects of exogenous β‑hydroxybutyrate on kainic acid‑induced epilepsy

Authors:
- Jianping Si
- Yingyan Wang
- Jing Xu
- Jiwen Wang
View Affiliations

Affiliations: Department of Pediatrics, The People's Hospital of Guangrao, Dongying, Shandong 257300, P.R. China, Department of Neurology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, P.R. China
Published online on: October 9, 2020 https://doi.org/10.3892/etm.2020.9307
Article Number: 177
Copyright: © Si et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to explore the potential anticonvulsant effects of β‑hydroxybutyrate (BHB) in a kainic acid (KA)‑induced rat epilepsy model. The KA‑induced rat seizure model was established and BHB was administrated intraperitoneally at a dose of 4 mmol/kg 30 min prior to KA injection. Hippocampal tissues were then obtained 1, 3 and 7 days following KA administration, following which the expression levels of neuron‑specific enolase (NSE) and glial fibrillary acidic protein (GFAP) were measured using a double immunofluorescence labeling method. In addition, the contents of glutathione (GSH), γ‑aminobutyric acid (GABA) and ATP were measured using ELISA. Pretreatment with BHB markedly increased the expression of NSE after KA injection compared with that in the normal saline (NS) + KA group, suggesting that the application of BHB could alleviate neuronal damage in rats. The protective effect of BHB may be associated with suppressed inflammatory responses, which was indicated by the observed inhibition of GFAP expression in rats in the BHB + KA group compared with that in the NS + KA group. It was also found that GSH and GABA contents were notably increased after the rats were pretreated with BHB compared with those in the NS + KA group. To conclude, the application of exogenous BHB can serve as a novel therapeutic agent for epilepsy.

View Figures

View References

1	Chang BS and Lowenstein DH: Epilepsy. N Engl J Med. 349:1257–1266. 2003.PubMed/NCBI View Article : Google Scholar
2	Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, et al: ILAE official report: A practical clinical definition of epilepsy. Epilepsia. 55:475–482. 2014.PubMed/NCBI View Article : Google Scholar
3	GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet. 388:1545–1602. 2016.PubMed/NCBI View Article : Google Scholar
4	Kernich CA: Patient and family fact sheet Epilepsy. Neurologist. 9:265–266. 2003.PubMed/NCBI View Article : Google Scholar
5	GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet. 388:1459–1544. 2016.PubMed/NCBI View Article : Google Scholar
6	GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 385:117–171. 2015.PubMed/NCBI View Article : Google Scholar
7	Brodie MJ, Elder AT and Kwan P: Epilepsy in later life. Lancet Neurol. 8:1019–1030. 2009.PubMed/NCBI View Article : Google Scholar
8	Eadie MJ: Shortcomings in the current treatment of epilepsy. Expert Rev Neurother. 12:1419–1427. 2012.PubMed/NCBI View Article : Google Scholar
9	Kwan P and Brodie MJ: Early identification of refractory epilepsy. N Engl J Med. 342:314–319. 2000.PubMed/NCBI View Article : Google Scholar
10	Wei CX, Bian M and Gong GH: Current research on antiepileptic compounds. Molecules. 20:20741–20776. 2015.PubMed/NCBI View Article : Google Scholar
11	Suzuki Y, Takahashi H, Fukuda M, Hino H, Kobayashi K, Tanaka J and Ishii E: β-Hydroxybutyrate alters GABA-transaminase activity in cultured astrocytes. Brain Res. 1268:17–23. 2009.PubMed/NCBI View Article : Google Scholar
12	Samoilova M, Weisspapir M, Abdelmalik P, Velumian AA and Carlen PL: Chronic in vitro ketosis is neuroprotective but not anti-convulsant. J Neurochem. 113:826–835. 2010.PubMed/NCBI View Article : Google Scholar
13	Maalouf M and Rho JM: Oxidative impairment of hippocampal long-term potentiation involves activation of protein phosphatase 2A and is prevented by ketone bodies. J Neurosci Res. 86:3322–3330. 2008.PubMed/NCBI View Article : Google Scholar
14	Likhodii SS and Burnham WM: Ketogenic diet: Does acetone stop seizures? Med Sci Monit. 8:HY19–HY24. 2002.PubMed/NCBI
15	Abdelmalik PA, Shannon P, Yiu A, Liang P, Adamchik Y, Weisspapir M, Samoilova M, Burnham WM and Carlen PL: Hypoglycemic seizures during transient hypoglycemia exacerbate hippocampal dysfunction. Neurobiol Dis. 26:646–660. 2007.PubMed/NCBI View Article : Google Scholar
16	Yum MS, Ko TS and Dong WK: Anticonvulsant effects of β-hydroxybutyrate in mice. J Epilepsy Res. 2:29–32. 2012.PubMed/NCBI View Article : Google Scholar
17	Yum MS, Ko TS and Kim DW: β-Hydroxybutyrate increases the pilocarpine-induced seizure threshold in young mice. Brain Dev. 34:181–184. 2012.PubMed/NCBI View Article : Google Scholar
18	Minlebaev M and Khazipov R: Antiepileptic effects of endogenous beta-hydroxybutyrate in suckling infant rats. Epilepsy Res. 95:100–109. 2011.PubMed/NCBI View Article : Google Scholar
19	Thio LL, Wong M and Yamada KA: Ketone bodies do not directly alter excitatory or inhibitory hippocampal synaptic transmission. Neurology. 54:325–331. 2000.PubMed/NCBI View Article : Google Scholar
20	Si J, Wang S, Liu N, Yang X, Wang Y, Li L, Wang J and Lv X: Anticonvulsant effect of exogenous β-hydroxybutyrate on kainic acid-induced epilepsy. Exp Ther Med. 14:765–770. 2017.PubMed/NCBI View Article : Google Scholar
21	National Research Council: Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press (US); 2011. Available from: urihttps://www.ncbi.nlm.nih.gov/books/NBK54050/simplehttps://www.ncbi.nlm.nih.gov/books/NBK54050/ doi: 10.17226/12910ß.
22	Racine RJ: Modification of seizure activity by electrical stimulation II Motor seizure. Electroencephalogr Clin Neurophysiol. 32:281–294. 1972.PubMed/NCBI View Article : Google Scholar
23	Xie G, Tian W, Wei T and Liu F: The neuroprotective effects of β-hydroxybutyrate on Aβ-injected rat hippocampus in vivo and in Aβ-treated PC-12 cells in vitro. Free Radic Res. 49:139–150. 2015.PubMed/NCBI View Article : Google Scholar
24	Bindra A, Kaushal A, Prabhakar H, Chaturvedi A, Chandra PS, Tripathi M, Subbiah V, Sathianathan S, Banerjee J and Prakash C: Neuroprotective role of dexmedetomidine in epilepsy surgery: A preliminary study. Neurol India. 67:163–168. 2019.PubMed/NCBI View Article : Google Scholar
25	Maiti R, Mishra BR, Sanyal S, Mohapatra D, Parida S and Mishra A: Effect of carbamazepine and oxcarbazepine on serum neuron-specific enolase in focal seizures: A randomized controlled trial. Epilepsy Res. 138:5–10. 2017.PubMed/NCBI View Article : Google Scholar
26	Yardimoğlu M, Ilbay G, Dalcik C, Dalcik H, Sahin D and Ates N: Immunocytochemistry of neuron specific enolase (NSE) in the rat brain after single and repeated epileptic seizures. Int J Neurosci. 118:981–993. 2008.PubMed/NCBI View Article : Google Scholar
27	Jacque CM, Vinner C, Kujas M, Raoul M, Racadot J and Baumann NA: Determination of glial fibrillary acidic protein (GFAP) in human brain tumors. J Neurol Sci. 35:147–155. 1978.PubMed/NCBI View Article : Google Scholar
28	Venkatesh K, Srikanth L, Vengamma B, Chandrasekhar C, Sanjeevkumar A, Mouleshwara Prasad BC and Sarma PV: In vitro differentiation of cultured human CD34+ cells into astrocytes. Neurol India. 61:383–388. 2013.PubMed/NCBI View Article : Google Scholar
29	Alese OO and Mabandla MV: Upregulation of hippocampal synaptophysin, GFAP and mGluR3 in a pilocarpine rat model of epilepsy with history of prolonged febrile seizure. J Chem Neuroanat. 100(101659)2019.PubMed/NCBI View Article : Google Scholar
30	Puttachary S, Sharma S, Stark S and Thippeswamy T: Seizure-induced oxidative stress in temporal lobe epilepsy. Biomed Res Int. 2015(745613)2015.PubMed/NCBI View Article : Google Scholar
31	Yuen AWC, Keezer MR and Sander JW: Epilepsy is a neurological and a systemic disorder. Epilepsy Behav. 78:57–61. 2018.PubMed/NCBI View Article : Google Scholar
32	Pearson-Smith JN and Patel M: Metabolic dysfunction and oxidative stress in epilepsy. Int J Mol Sci. 18(2365)2017.PubMed/NCBI View Article : Google Scholar
33	Pompella A, Visvikis A, Paolicchi A, De Tata V and Casini AF: The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol. 66:1499–1503. 2003.PubMed/NCBI View Article : Google Scholar
34	Lutchmansingh FK, Hsu JW, Bennett FI, Badaloo AV, McFarlane-Anderson N, Gordon-Strachan GM, Wright-Pascoe RA, Jahoor F and Boyne MS: Glutathione metabolism in type 2 diabetes and its relationship with microvascular complications and glycemia. PLoS One. 13(e0198626)2018.PubMed/NCBI View Article : Google Scholar
35	Sprietsma JE: Cysteine, glutathione (GSH) and zinc and copper ions together are effective, natural, intracellular inhibitors of (AIDS) viruses. Med Hypotheses. 52:529–538. 1999.PubMed/NCBI View Article : Google Scholar
36	Guo Q, Liu S, Wang S, Wu M, Li Z and Wang Y: Beta-hydroxybutyric acid attenuates neuronal damage in epilepticmice. Acta Histochem. 121:455–459. 2019.PubMed/NCBI View Article : Google Scholar
37	Bhagat K, Singh JV, Pagare PP, Kumar N, Sharma A, Kaur G, Kinarivala N, Gandu S, Singh H, Sharma S and Bedi PMS: Rational approaches for the design of various GABA modulators and their clinical progression. Mol Divers 2020 (Epub ahead of print).
38	Treiman DM: GABAergic mechanisms in epilepsy. Epilepsia. 42 (Suppl 3):S8–S12. 2001.PubMed/NCBI View Article : Google Scholar
39	Cepeda C, Levinson S, Nariai H, Yazon VW, Tran C, Barry J, Oikonomou KD, Vinters HV, Fallah A, Mathern GW and Wu JY: Pathological high frequency oscillations associate with increased GABA synaptic activity in pediatric epilepsy surgery patients. Neurobiol Dis. 134(104618)2020.PubMed/NCBI View Article : Google Scholar
40	Simeone TA, Simeone KA and Rho JM: Ketone bodies as anti-seizure agents. Neurochem Res. 42:2011–2018. 2017.PubMed/NCBI View Article : Google Scholar
41	Li J, O'Leary EI and Tanner GR: The ketogenic diet metabolite beta-hydroxybutyrate (β-HB) reduces incidence of seizure-like activity (SLA) in a Katp- and GABAb-dependent manner in a whole-animal Drosophila melanogaster model. Epilepsy Res. 133:6–9. 2017.PubMed/NCBI View Article : Google Scholar
42	Mejía-Toiber J, Montiel T and Massieu L: D-beta-hydroxybutyrate prevents glutamate-mediated lipoperoxidation and neuronal damage elicited during glycolysis inhibition in vivo. Neurochem Res. 31:1399–1408. 2006.PubMed/NCBI View Article : Google Scholar
43	Mudaliar S, Alloju S and Henry RR: Can a shift in fuel energetics explain the beneficial cardiorenal out-comes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 39:1115–1122. 2016.PubMed/NCBI View Article : Google Scholar
44	Lund TM, Ploug KB, Iversen A, Jensen AA and Jansen-Olesen I: The metabolic impact of β-hydroxybutyrate on neurotransmission: Reduced glycolysis mediates changes in calcium responses and KATP channel receptor sensitivity. J Neurochem. 132:520–531. 2015.PubMed/NCBI View Article : Google Scholar
45	Tanner G, Lutas A, Martínez-François JR and Yellen G: Single K ATP channel opening in response to action potential firing in mouse dentate granule neurons. J Neurosci. 31:8689–8696. 2011.PubMed/NCBI View Article : Google Scholar
46	Giménez-Cassina A, Martínez-François JR, Fisher JK, Szlyk B, Polak K, Wiwczar J, Tanner GR, Lutas A, Yellen G and Danial NN: BAD-dependent regulation of fuel metabolism and K(ATP) channel activity confers resistance to epileptic seizures. Neuron. 74:719–730. 2012.PubMed/NCBI View Article : Google Scholar
47	Soto-Mota A, Norwitz NG and Clarke K: Why a d-β-hydroxybutyrate monoester? Biochem Soc Trans. 48:51–59. 2020.PubMed/NCBI View Article : Google Scholar
48	Krishnan M, Hwang JS, Kim M, Kim YJ, Seo JH, Jung J and Ha E: β-hydroxybutyrate impedes the progression of Alzheimer's disease and atherosclerosis in ApoE-deficient mice. Nutrients. 12(471)2020.PubMed/NCBI View Article : Google Scholar
49	Norwitz NG, Hu MT and Clarke K: The mechanisms by which the ketone body D-β-hydroxybutyrate may improve the multiple cellular pathologies of Parkinson's disease. Front Nutr. 6(63)2019.PubMed/NCBI View Article : Google Scholar
50	Yum MS, Lee M, Woo DC, Kim DW, Ko TS and Velíšek L: β-Hydroxybutyrate attenuates NMDA-induced spasms in rats with evidence of neuronal stabilization on MR spectroscopy. Epilepsy Res. 117:125–132. 2015.PubMed/NCBI View Article : Google Scholar
51	Giordano C, Marchiò M, Timofeeva E and Biagini G: Neuroactive peptides as putative mediators of antiepileptic ketogenic diets. Front Neurol. 5(63)2014.PubMed/NCBI View Article : Google Scholar